Patents by Inventor Shinji Ashida
Shinji Ashida has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240082413Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.Type: ApplicationFiled: March 3, 2023Publication date: March 14, 2024Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Takeshi MASUDA, Hiroyuki NAITO, Takashi NAKADA, Masao YOSHIDA, Shinji ASHIDA, Hideki MIYAZAKI, Yuji KASUYA, Koji MORITA, Yuki ABE, Yusuke OGITANI
-
Publication number: 20240026030Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La—(CH2)n2—C(?O)—wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2—C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.Type: ApplicationFiled: September 12, 2023Publication date: January 25, 2024Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki NAITO, Yusuke OGITANI, Takeshi MASUDA, Takashi NAKADA, Masao YOSHIDA, Shinji ASHIDA, Koji MORITA, Hideki MIYAZAKI, Yuji KASUYA, Ichiro HAYAKAWA, Yuki ABE
-
Patent number: 11795236Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting positionType: GrantFiled: September 13, 2018Date of Patent: October 24, 2023Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Yusuke Ogitani, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Koji Morita, Hideki Miyazaki, Yuji Kasuya, Ichiro Hayakawa, Yuki Abe
-
Patent number: 11633493Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LF-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.Type: GrantFiled: March 24, 2020Date of Patent: April 25, 2023Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Takeshi Masuda, Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Hideki Miyazaki, Yuji Kasuya, Koji Morita, Yuki Abe, Yusuke Ogitani
-
Patent number: 11628223Abstract: A novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines represented by the [Formula 24], [Formula 25], [Formula 26], and/or [Formula 27].Type: GrantFiled: September 28, 2018Date of Patent: April 18, 2023Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Narihiro Toda, Yusuke Ota, Fuminao Doi, Masaki Meguro, Ichiro Hayakawa, Shinji Ashida, Takeshi Masuda, Takashi Nakada, Mitsuhiro Iwamoto, Naoya Harada, Tomoko Terauchi, Daisuke Okajima, Kensuke Nakamura, Hiroaki Uchida, Hirofumi Hamada
-
Publication number: 20230084707Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.Type: ApplicationFiled: April 5, 2022Publication date: March 16, 2023Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Narihiro TODA, Yusuke OTA, Fuminao DOI, Masaki MEGURO, Ichiro HAYAKAWA, Shinji ASHIDA, Takeshi MASUDA, Takashi NAKADA, Mitsuhiro IWAMOTO, Naoya HARADA, Tomoko TERAUCHI, Daisuke OKAJIMA, Kensuke NAKAMURA, Hiroaki UCHIDA, Hirofumi HAMADA
-
Patent number: 11583590Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.Type: GrantFiled: December 6, 2021Date of Patent: February 21, 2023Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Narihiro Toda, Yusuke Ota, Fuminao Doi, Masaki Meguro, Ichiro Hayakawa, Shinji Ashida, Takeshi Masuda, Takashi Nakada, Mitsuhiro Iwamoto, Naoya Harada, Tomoko Terauchi, Daisuke Okajima, Kensuke Nakamura, Hiroaki Uchida, Hirofumi Hamada
-
Patent number: 11584800Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.Type: GrantFiled: August 19, 2020Date of Patent: February 21, 2023Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Yusuke Ogitani, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Koji Morita, Hideki Miyazaki, Yuji Kasuya, Ichiro Hayakawa, Yuki Abe
-
Publication number: 20220395579Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.Type: ApplicationFiled: June 26, 2022Publication date: December 15, 2022Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Narihiro TODA, Yusuke OTA, Fuminao DOI, Masaki MEGURO, Ichiro HAYAKAWA, Shinji ASHIDA, Takeshi MASUDA, Takashi NAKADA, Mitsuhiro IWAMOTO, Naoya HARADA, Tomoko TERAUCHI, Daisuke OKAJIMA, Kensuke NAKAMURA, Hiroaki UCHIDA, Hirofumi HAMADA
-
Publication number: 20220168440Abstract: A novel antibody-pyrrolobenzodiazepine (PBD) derivative conjugate, a medicine having therapeutic effect against tumor with the antibody-drug conjugate, and a method for treating a tumor by using the antibody-drug conjugate or medicine.Type: ApplicationFiled: March 24, 2020Publication date: June 2, 2022Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Narihiro TODA, Yusuke OTA, Fuminao DOI, Masaki MEGURO, Ichiro HAYAKAWA, Shinji ASHIDA, Takeshi MASUDA, Takashi NAKADA
-
Patent number: 11344270Abstract: An X-ray diagnostic apparatus according to an embodiment includes a support frame and processing circuitry. The support frame supports an X-ray generator and an X-ray detector. The processing circuitry is configured to, when rotational acquisitions are performed multiple times after a contrast agent is injected one time, previously set a generation condition of an X-ray that is generated by the X-ray generator for each of the rotational acquisitions, the rotational acquisitions being performed while the support frame is rotated around a subject.Type: GrantFiled: March 6, 2020Date of Patent: May 31, 2022Assignees: CANON MEDICAL SYSTEMS CORPORATIONInventors: Shinji Ashida, Satoru Ohishi
-
Publication number: 20220125943Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.Type: ApplicationFiled: December 6, 2021Publication date: April 28, 2022Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Narihiro TODA, Yusuke OTA, Fuminao DOI, Masaki MEGURO, Ichiro HAYAKAWA, Shinji ASHIDA, Takeshi MASUDA, Takashi NAKADA, Mitsuhiro IWAMOTO, Naoya HARADA, Tomoko TERAUCHI, Daisuke OKAJIMA, Kensuke NAKAMURA, Hiroaki UCHIDA, Hirofumi HAMADA
-
Patent number: 11261261Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.Type: GrantFiled: August 19, 2020Date of Patent: March 1, 2022Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Yusuke Ogitani, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Koji Morita, Hideki Miyazaki, Yuji Kasuya, Ichiro Hayakawa, Yuki Abe
-
Patent number: 11185594Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the formula: L1-L2-LP-NH—(CH2)n1-La-Lb-Lc or -L1-L2-LP- wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the terminal Lc or LP with the nitrogen atom of the amino group at position 1 as the connecting position.Type: GrantFiled: April 6, 2015Date of Patent: November 30, 2021Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Hideki Miyazaki, Yuji Kasuya, Koji Morita, Yusuke Ogitani, Yuki Abe
-
Patent number: 10973924Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.Type: GrantFiled: September 26, 2018Date of Patent: April 13, 2021Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Takeshi Masuda, Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Hideki Miyazaki, Yuji Kasuya, Koji Morita, Yuki Abe, Yusuke Ogitani
-
Publication number: 20200385486Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.Type: ApplicationFiled: August 19, 2020Publication date: December 10, 2020Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki NAITO, Yusuke OGITANI, Takeshi MASUDA, Takashi NAKADA, Masao YOSHIDA, Shinji ASHIDA, Koji MORITA, Hideki MIYAZAKI, Yuji KASUYA, Ichiro HAYAKAWA, Yuki ABE
-
Publication number: 20200282073Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LF-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.Type: ApplicationFiled: March 24, 2020Publication date: September 10, 2020Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Takeshi MASUDA, Hiroyuki NAITO, Takashi NAKADA, Masao YOSHIDA, Shinji ASHIDA, Hideki MIYAZAKI, Yuji KASUYA, Koji MORITA, Yuki ABE, Yusuke OGITANI
-
Publication number: 20200261594Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.Type: ApplicationFiled: September 28, 2018Publication date: August 20, 2020Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Narihiro TODA, Yusuke OTA, Fuminao DOI, Masaki MEGURO, Ichiro HAYAKAWA, Shinji ASHIDA, Takeshi MASUDA, Takashi NAKADA, Mitsuhiro IWAMOTO, Naoya HARADA, Tomoko TERAUCHI, Daisuke OKAJIMA, Kensuke NAKAMURA, Hiroaki UCHIDA, Hirofumi HAMADA
-
Patent number: 10729782Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula (I) is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- or -L1-L2-LP- wherein the antibody is connected to the terminal of L1, the antitumor compound is connected to the terminal of Lc or LP, and any one or two or more of linkers of L1, L2, and LP has a hydrophilic structure.Type: GrantFiled: November 22, 2017Date of Patent: August 4, 2020Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Takeshi Masuda, Hideki Miyazaki, Yuji Kasuya, Yuki Abe, Yusuke Ogitani
-
Publication number: 20200205762Abstract: An X-ray diagnostic apparatus according to an embodiment includes a support frame and processing circuitry. The support frame supports an X-ray generator and an X-ray detector. The processing circuitry is configured to, when rotational acquisitions are performed multiple times after a contrast agent is injected one time, previously set a generation condition of an X-ray that is generated by the X-ray generator for each of the rotational acquisitions, the rotational acquisitions being performed while the support frame is rotated around a subject.Type: ApplicationFiled: March 6, 2020Publication date: July 2, 2020Applicants: CANON MEDICAL SYSTEMS CORPORATIONInventors: Shinji ASHIDA, Satoru OHISHI